NEW YORK (Reuters) – Merck & Co Inc and Japan’s Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai’s cancer drug Lenvima, which is already approved in dozens of countries for two uses.
Source: Reuters Medical News